Keywords
Dyslipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ezetimibe
Cholesterol
LDL
Prospective Studies
How to Cite
Abstract
Objective: This study compared 12-week LDL-C reduction and target attainment with atorvastatin 20 mg alone versus atorvastatin 20 mg plus ezetimibe 10 mg.
Methods: This single-centre prospective observational cohort study was conducted at a tertiary care hospital in Rawalpindi, Pakistan, from March to July 2026. Adults aged 30 to 70 years with T2DM and LDL-C ≥70 mg/dL were consecutively enrolled in two routine-care cohorts according to the regimen prescribed by their treating physician. Seventy participants received atorvastatin 20 mg once daily, and 70 received atorvastatin 20 mg plus ezetimibe 10 mg once daily. The primary outcome was the absolute change in LDL-C levels at week 12. An analysis of covariance model was used, with week-12 LDL-C as the dependent variable, treatment group as the fixed factor, and baseline LDL-C as the covariate.
Results: All 140 participants completed the follow-up. The mean baseline LDL-C was 125.3 ± 23.1 mg/dL with atorvastatin alone and 127.9 ± 24.8 mg/dL with combination therapy. The mean LDL-C reductions were 35.6 and 54.0 mg/dL, respectively. After adjusting for baseline LDL-C, combination therapy was associated with an additional 18.4 mg/dL reduction (95% CI 12.8 to 24.0; p<0.001). LDL-C < 70 mg/dL was achieved by 26 of 70 participants (37.1%) and 45 of 70 (64.3%) (p=0.001). A reduction of at least 50% occurred in 9 of 70 (12.9%) and 21 of 70 (30.0%) patients (p=0.01). Adverse events were recorded in 10 of 70 (14.3%) and 12 of 70 (17.1%) participants (p=0.64).
Conclusion: Atorvastatin 20 mg plus ezetimibe 10 mg was associated with greater 12-week LDL-C reduction and target attainment than atorvastatin 20 mg alone. The observational design, short follow-up, and limited sample size preclude causal inference, safety equivalence assessment, and assessment of cardiovascular benefits.
MeSH Keywords: Diabetes Mellitus, Type 2; Dyslipidemias; Hydroxymethylglutaryl-CoA.
References
Basit A, Fawwad A, Qureshi H, Shera AS; NDSP Members. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016-2017. BMJ Open. 2018;8:e020961. https://doi.org/10.1136/bmjopen-2017-020961
Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, et al. Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan. BMJ Open. 2019;9:e025300. https://doi.org/10.1136/bmjopen-2018-025300
American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: standards of care in diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S216-S245. https://doi.org/10.2337/dc26-S010
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. https://doi.org/10.1093/eurheartj/ehad192
Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and treatment of dyslipidemia in diabetes. Curr Cardiol Rep. 2021;23(4):26. https://doi.org/10.1007/s11886-021-01455-w
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366-1418. https://doi.org/10.1016/j.jacc.2022.07.006
Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. https://doi.org/10.1093/eurheartj/ehaf190
Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380-390. https://doi.org/10.1016/S0140-6736(22)00916-3
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, et al. The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes mellitus. Diabetes Metab J. 2023;47(6):818-825. https://doi.org/10.4093/dmj.2023.0171
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT. Circulation. 2018;137(15):1571-1582. https://doi.org/10.1161/CIRCULATIONAHA.117.030950
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. https://doi.org/10.1016/S0140-6736(07)61602-X
Khan SU, Yedlapati SH, Lone AN, Hao Q, Guyatt G, Delvaux N, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022;377:e069116. https://doi.org/10.1136/bmj-2021-069116
Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832-845. https://doi.org/10.1016/S0140-6736(22)01545-8
Kitchlew R, Mukhtar H, Farooqi M, Ijaz MT, Aslam Z. Statin practices for atherosclerotic cardiovascular disease prevention: a cross-sectional analysis of guideline adherence in a high-risk local patient population. J Pak Med Assoc. 2025;75(11):1747-1751. https://doi.org/10.47391/JPMA.20228
Hussain A, Muhammad Z, Ali I, Tariq SA, Hussain A, Siraj S. Pattern of dyslipidemia and associated factors in coronary artery disease patients in Khyber Pakhtunkhwa: a cross-sectional secondary data analysis. Pak J Med Sci. 2023;39(5):1416-1421. https://doi.org/10.12669/pjms.39.5.7382
Waheed A, Nafisa A, Omer W, Amin H, Tariq A, Umar M. Seven-year trend analysis of dyslipidemia among patients reporting to a tertiary care hospital in Rawalpindi, Pakistan. J Rawalpindi Med Coll. 2025;29(3). https://doi.org/10.37939/jrmc.v29i3.2847
Soroush N, Nekouei Shahraki M, Mohammadi Jouabadi S, Amiri M, Aribas E, Stricker BH, et al. Statin therapy and cardiovascular protection in type 2 diabetes: the role of baseline LDL-C levels. A systematic review and meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2024;34(9):2021-2033. https://doi.org/10.1016/j.numecd.2024.04.015
Lee YB, Kim B, Han K, Kim JA, Roh E, Hong SH, et al. Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: a propensity-matched nationwide cohort study. J Lipid Atheroscler. 2021;10(3):303-312. https://doi.org/10.12997/jla.2021.10.3.303
Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative effectiveness of statins on non-high-density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022;376:e067731. https://doi.org/10.1136/bmj-2021-067731
Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, et al. Comparative lipid-lowering and lipid-increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020;2020:3987065. https://doi.org/10.1155/2020/3987065.
Shah M, Sundar G, Shah S. Ocular trauma score revisited–making sense of it all. Latin American Journal of Ophthalmology. 2019;4:2. https://doi.org/10.25259/LAJO_8_2019
Unver, Yaprak Banu MD, Kapran, Ziya MD, Acar, Nur MD, et al. Ocular Trauma Score in Open-Globe Injuries. The Journal of Trauma: Injury, Infection, and Critical Care 66(4):p 1030-1032, April 2009. https://doi.org/ 10.1097/TA.0b013e3181883d83
Weichel ED, Colyer MH, Ludlow SE, Bower KS, Eiseman AS. Combat ocular trauma visual outcomes during operations iraqi and enduring freedom. Ophthalmology. 2008;115(12):2235-45. https://doi.org/.10.1016/j.ophtha.2008.08.033
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2026 Hafsa Ibrahim, Fuad Ahmad Siddiqi, Ejaz Ahmad, Kanaz Ahmad Siddiqi, Muhammad Naeem Qureshi, Sidra Saeed